AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025.
The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC).
This will be the first presentation of clinical data from a 212Pb-PSMA therapy at a major oncology conference – an important milestone in advancing targeted alpha therapies for prostate cancer and a clear demonstration of AdvanCell’s leadership in radioligand therapy. The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring the potential of 212Pb-ADVC001 to enhance therapeutic options for patients with metastatic prostate cancer.
The abstract is available online on the ESMO website (link), and features data as of a May 9, 2025 cut-off. The poster to be presented at ESMO will include updated safety and efficacy data and additional treatment cohorts.
Details of the abstract and presentation:
Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TheraPb Trial
- Presenter: Aaron Hansen, MD, BSc, MBBS, FRACP, Princess Alexandra Hospital, Brisbane, Australia
- Presentation Number: 2388P
- Session: Prostate Cancer Poster Session
- Session Time/ Place: Saturday, October 18 / 12:00-12:45 PM CET / Hall 25
- Poster Display Time: 9:00 AM – 5:00 PM CET
About the TheraPb trial
The TheraPb trial (NCT05720130) is a prospective, open-label Phase 1/2 dose-escalation and expansion study designed to determine the safety and tolerability of escalating doses of 212Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) during the dose-finding Phase 1b. The Phase 2 expansion will assess the efficacy and safety of 212Pb-ADVC001 at the recommended Phase 2 doses across three indications. The trial incorporates randomization and dose optimization elements to rigorously evaluate optimal dosing strategies of 212Pb-ADVC001 in PSMA-positive mCRPC and in hormone-sensitive prostate cancer (mHSPC).
About 212Pb-ADVC001
212Pb-ADVC001 is a novel, proprietary and patented small molecule PSMA-targeting radioligand with optimized physicochemical properties labelled with 212Pb, an alpha-emitting payload (radionuclide) with a high dose rate, short half-life (10.6 hours) and simple decay scheme. 212Pb-ADVC001 is designed to deliver radiation at a cellular level to more effectively kill prostate cancer cells while minimizing toxicity.
About AdvanCell
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By leveraging its proprietary Lead-212 platform, advanced and scalable manufacturing capabilities, cutting-edge science and world-class clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for patients with cancer globally.
For more information, visit www.advancell.com.au and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013316172/en/
Contacts
Andrew Adamovich, CEO
contact@advancell.com.au
For media inquiries, please contact:
MEDiSTRAVA
Mark Swallow, Frazer Hall, Sylvie Berrebi
advancell@medistrava.com
+44 (0)20 3928 6700
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 202513.10.2025 01:05:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. “We are encouraged by the positive findings being presented with our TGFβR2×PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "There remains a significant need for new treatment options for patients with advanced solid tumors like colorectal cancer and pancreatic ductal adenocarcinoma and we look forward to providing updates on these clinical development programs.” Details on INCA33890 and INCB161734 oral presentations at ESMO include: INCA33890 (PD-1/TGFβR
Day Two of the 11th World FZO Congress Highlights the Role of Digitization and Sustainability in Shaping the Future of Free Zones11.10.2025 17:52:00 EEST | Press release
The World Free Zones Organization’s 11th annual World Congress continued its agenda today with a focus on the role of digitization and sustainability in the future of free zones and the mechanisms for enhancing their position as strategic trade gateways. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251011933300/en/ Dr Al Zarooni and President of CIRD launching the global institute (Photo: AETOSWire) The day’s sessions featured a series of sessions addressing critical themes such as the digitization of trade corridors, the impact of the OECD Global Minimum Tax, and the role of free zones as regional trade gateways. Sustainability took centre stage with sessions focusing on the transition to net-zero through renewable energy, circular economy models, and green financing frameworks. Speakers underscored that decarbonization is not only a climate imperative but also a competitive advantage for the next generation of free zones
IonQ to Participate in GITEX Dubai 2025, Showcasing Advancements in Quantum Infrastructure and Security10.10.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading quantum company, today announced its participation in GITEX Global 2025, one of the world’s largest and most influential technology exhibitions, taking place October 13-17 at the Dubai World Trade Centre. IonQ executives and partners will highlight advancements in quantum computing, secure infrastructure, and commercial applications that are accelerating enterprise adoption of quantum technologies. Rima Alameddine, Chief Revenue Officer at IonQ, will speak on the panel “Cracking the Quantum Code: How to Build a Profitable Business in the Quantum Economy,” on October 14, in Hall 10, AI stage. This session will convene global quantum leaders to discuss the path from breakthrough science to viable commercial success, including how to unlock investment, scale quantum solutions, and deliver near-term value across sectors. Grégoire Ribordy, Co-founder and CEO at ID Quantique, an IonQ company, will also speak on October 16 during the panel “Establishing Quantum-Sa
IonQ to Participate in ComoLake2025, Advancing Quantum Collaboration in Italy10.10.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading quantum company, today announced its participation in the ComoLake2025 Digital Innovation Forum, one of Italy’s most prominent technology events focused on digital transformation, infrastructure, and innovation policy. At ComoLake2025, taking place October 14–17 at the Villa Erba International Exhibition and Congress Center in Cernobbio, Niccolò de Masi, Chairman and CEO at IonQ, will deliver a special address, offering strategic insights into how quantum computing is reshaping infrastructure, industry, and Europe’s digital leadership. Marco Pistoia, Senior Vice President of Industry Relations at IonQ, will participate in the round table “Pan-European Quantum Industry Forum - Dialogue between Industry, Politics, and Research for Europe's Quantum Leadership” focused on strengthening Europe’s position in the global quantum landscape. Organized by the Fondazione Innovazione Digitale, ComoLake2025 is a four-day forum that draws over 1,400 participants and 215 s
Axway Named a Leader in the 2025 Gartner® Magic Quadrant™ for API Management for the 10 th Time10.10.2025 21:20:00 EEST | Press release
Axway, a 74Software company (Euronext: 74SW), a global leader in federated API management and enterprise integration, is recognized by Gartner as a Leader in the 2025 Magic Quadrant™ for API Management1 – marking the 10th time Axway has been positioned as a Leader in the report. Based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute, we believe the evaluation highlights the strength of Axway’s Amplify API Management offering and its ability to address the growing challenges of API sprawl, governance, and AI-driven integration. In companion research issued by Gartner along with the report, Critical Capabilities for API Management, Axway received the highest score (3.6 out of 5.0) for the Distributed API Management Use Case for the third consecutive year.2 “This is the tenth time Axway is named a Leader in this report. For us, this feels like a strong validation of Axway’s vision and consistent ability to deliver,” said Roland Royer,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom